[Intravesical or intrarectal instillation of maalox for the treatment of radiation cystitis or proctitis].
Intravesical or intrarectal instillation of Maalox, a well-known material for protection of mucous epithelia, was performed in 3 cases of radiation cystitis and one case of radiation proctitis, resulting insuccessful control of hemorrhage. 4 cases of uterine cervical cancer with radiotherapy, including 2 cases of primary and 2 cases of postoperative radiotherapy, were managed by Maalox treatment with intervals of one to nine years between radiotherapy and Maalox instillation. One of the three patients of hemorrhagic cystitis, who had received internal iliac arterial embolization at the another hospital, was to be performed the operation of the urinary tract diversion. 50-100 ml of original or 1/2 diluted Maalox was instilled into urinary bladder or rectum with clump of catheter for 30 min. to 1 hr. after sufficient irrigation with 500 ml of 100 times diluted isodine. Blood transfusion for anemia was done in all cases, and antibiotics, or anticoagulant agents were systematically administered in some cases. Macrohematuria or melena ceased within 2 to 8 days after initiation of Maalox therapy in all cases. In one of the three cases of hemorrhagic cystitis, macroscopic hematuria, which reappeared one year later, was also successfully treated by Maalox therapy. In a case of radiation proctitis, though the melena disappeared in 5 days, diarrhea continued and the patient died of the primary disease two months later with the formation of rectovaginal fistula. No ultimate way of treatment of radiation hemorrhagic cystitis or proctitis has been established, though both of them were clinically important and serious side effects of radiotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Kawagoe
K
K
Kawana
T
T
D000368:Aged; D000536:Aluminum Hydroxide / Q000008:administration & dosage* / Q000627:therapeutic use; D000863:Antacids / Q000008:administration & dosage* / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage*; D008276:Magnesium Hydroxide / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011349:Proctitis / Q000188:drug therapy* / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects*; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy
D000863:Antacids; D004338:Drug Combinations; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000536:Aluminum Hydroxide; D008274:Magnesium; D008276:Magnesium Hydroxide